A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers.
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...
Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...
New research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Cancer a life-threatening disease can spread or metastasise from its original location to other parts of the body The lungs ...
Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...
While those are the most common sites for prostate cancer bone metastasis, any bones in your body could be a potential target. Prostate cancer can involve the liver, intestines, brain, lungs, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback